These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 3872261)

  • 41. Binding characteristics of three complement dependent assays for the detection of immune complexes in human serum.
    Krieger G; Kneba M; Bolz I; Volling P; Wessels J; Nagel GA
    J Clin Lab Immunol; 1985 Nov; 18(3):129-34. PubMed ID: 3878887
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The macromolecular structure of the first component of complement.
    Assimeh SN; Painter RH
    J Immunol; 1975 Aug; 115(2):488-94. PubMed ID: 807640
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Monomeric complement-activating IgG paraproteins.
    Trendelenburg M; Hess C; Kondo-Oestreicher M; Tissot JD; Späth P; Schifferli JA
    J Immunol; 1999 Dec; 163(12):6924-32. PubMed ID: 10586095
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Stepwise dissociation of subcomponents of C1, the first component of human complement, upon activation on an affinity sorbent].
    Kozlov LV; Shoĭbonov BB; Ivanov AE; Zubov VP; Antonov VK
    Biokhimiia; 1989 Oct; 54(10):1745-51. PubMed ID: 2605275
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Leukocyte-derived complement inhibitor. IV. The functional properties of C1 bound to erythrocytes pretreated with leukocyte culture supernatant.
    Bernard A; Walter W; Teshima H; Boumsell L; Good RA; Day NK
    J Immunol; 1976 Oct; 117(4):1117-26. PubMed ID: 977945
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chronic liver disease: the detection and characterization of circulating immune complexes.
    Brown SE; Steward MW; Viola L; Howard CR; Murray-Lyon IM
    Immunology; 1983 Aug; 49(4):673-83. PubMed ID: 6307866
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clearance of soluble aggregates of human immunoglobulin G in healthy volunteers and chimpanzees.
    Lobatto S; Daha MR; Voetman AA; Evers-Schouten JH; Van Es AA; Pauwels EK; Van Es LA
    Clin Exp Immunol; 1987 Jul; 69(1):133-41. PubMed ID: 3652528
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Virus-induced immune complex disease: genetic control of C1q binding complexes in the circulation of mice persistently infected with lymphocytic choriomeningitis virus.
    Oldstone MB; Tishon A; Buchmeier MJ
    J Immunol; 1983 Feb; 130(2):912-8. PubMed ID: 6217255
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The unactivated form of the first component of human complement, C1.
    Gigli I; Porter RR; Sim RB
    Biochem J; 1976 Sep; 157(3):541-8. PubMed ID: 985398
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Defective function of the mononuclear phagocytic system in rats with chronic nephritis. Evidence of a decreased degradation of IgG aggregates by Kupffer cells.
    Herrero-Beaumont G; Egido J; Sancho J; González E; Castañeda S; Escanero JF
    Immunology; 1988 Jan; 63(1):87-92. PubMed ID: 3338821
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of liver endothelial and Kupffer cells in clearance of human C1q in rats.
    Coremans IE; Bogers WM; Stad RK; van der Voort EA; Prins FA; van Rooijen N; Breedveld FC; Daha MR
    Eur J Immunol; 1993 Aug; 23(8):1942-7. PubMed ID: 8344357
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antibody density on rat red cells determines the rate of activation of the complement component C1.
    Hughes-Jones NC; Gorick BD; Howard JC; Feinstein A
    Eur J Immunol; 1985 Oct; 15(10):976-80. PubMed ID: 2996908
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The mechanism of synergistic complement-mediated lysis of rat red cells by monoclonal IgG antibodies.
    Hughes-Jones NC; Gorick BD; Howard JC
    Eur J Immunol; 1983 Aug; 13(8):635-41. PubMed ID: 6603980
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antibody-independent C1 activation by E. coli.
    Tenner AJ; Ziccardi RJ; Cooper NR
    J Immunol; 1984 Aug; 133(2):886-91. PubMed ID: 6376630
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The development of a C1q anti-C1q immunoadsorbent for removal of immune complexes from plasma.
    Bratt T; Ohlson S
    J Clin Lab Immunol; 1988 Dec; 27(4):191-5. PubMed ID: 3266946
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tumoricidal response following perfusion over immobilized protein A: identification of immunoglobulin oligomers in serum after perfusion and their partial characterization.
    Balint J; Ikeda Y; Langone JJ; Shearer WT; Daskal I; Meek K; Cook G; Henry J; Terman DS
    Cancer Res; 1984 Feb; 44(2):734-43. PubMed ID: 6607106
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Kupffer cell depletion in vivo results in preferential elimination of IgG aggregates and immune complexes via specific Fc receptors on rat liver endothelial cells.
    Bogers WM; Stad RK; Janssen DJ; van Rooijen N; van Es LA; Daha MR
    Clin Exp Immunol; 1991 Nov; 86(2):328-33. PubMed ID: 1934600
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interaction between fibronectin and C1q in rheumatoid synovial fluid and normal plasma.
    Carsons SE; Schwartzman S; Diamond HS; Berkowitz E
    Clin Exp Immunol; 1988 Apr; 72(1):37-42. PubMed ID: 3135129
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Influence of aggregate size on the binding and activation of the first component of human complement by soluble IgG aggregates.
    Doekes G; Vanes LA; Daha MR
    Immunology; 1982 Apr; 45(4):705-13. PubMed ID: 7068172
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The role of immune complexes in the activation of the first component of human complement.
    Ziccardi RJ
    J Immunol; 1984 Jan; 132(1):283-8. PubMed ID: 6317744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.